NKT Thera Closes $8M VC Round to Develop Rxs Based on NK Cell IP from Boston Institutions | GenomeWeb

NKT Therapeutics, a company developing treatments for inflammatory disease based on IP licensed from a trio of Harvard Medical School-affiliated research hospitals, said this week that it has closed an $8 million Series A financing round to progress an early-stage pipeline of therapeutic antibodies targeting natural killer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Apr
11
Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.